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Introduction
During the last 10 years, polyoma BK-virus associated
nephropathy (PVAN) has emerged as a serious
complication in renal transplant recipients [1]. Due to
the establishment of an accurate non-invasive screen-
ing procedure measuring polyomavirus BK-viraemia,
BK-viruria and decoy cells in urine, PVAN can be
diagnosed at early stages [2]. This allows for timely
therapeutic intervention, which has significantly
reduced the incidence of severe PVAN courses includ-
ing graft loss [3,4].
Management of PVAN is mainly based on a
reduction of the immunosuppressive drugs, while
the impact of anti-viral therapy is not yet clear [5].
This strategy bears the inherent risk that allograft
rejection may arise, which is difficult to differentiate
from an immune response to the BK-virus, because
both entities can present as morphologically and
molecularly indistinguishable, with interstitial infil-
trates and tubulitis [1,5–7]. Therefore, more data
regarding the natural course of PVAN under reduced
immunosuppression might be helpful to illuminate the
scope of post-intervention responses.
Case report
A 37-year-old woman had end-stage renal failure due
to a nephropathy of unknown origin. She was highly
sensitized as a consequence of two blood transfusions
and two pregnancies (peak CDC-PRA 78%, peak
FlowPRATM class I 93%, FlowPRATM class II
negative). After being on haemodialysis for 9 years,
she received a kidney from a 7-year-old deceased
donor. There were three HLA-mismatches (recipient:
HLA-A3/24, B7/55, DR4/13; donor: HLA-A2/24,
B7/38, DR11/13) and the recipient had two donor-
specific HLA-antibodies (DSA) detectable in three
historic sera (A2 and B38; determined by FlowPRATM
single-antigen flow-beads). Flow-cytometric T- and
B-cell cross-matches were positive with historic sera,
but negative with the current one. The patient was
considered to be at high risk for rejection and received
an induction therapy consisting of polyclonal anti-
T-lymphocyte globulin (ATG-Fresenius) as well as
intravenous immunoglobulins (IvIg) [8]. Maintenance
immunosuppression consisted of tacrolimus, mycophe-
nolate mofetil (MMF) and steroids.
Figure 1 summarizes the course of immunosuppres-
sive therapy, allograft function and BK-virus activity;
Figure 2 demonstrates the histology of the four
allograft biopsies obtained in this patient. The allograft
had an immediate good function and serum creatinine
dropped to 140 mmol/l by day 10 post-transplant.
On day 21, serum creatinine rose to 308 mmol/l and
the first allograft biopsy was obtained. The diagnosis
of antibody-mediated rejection was made based on
the presence of thrombotic microangiopathy, diffuse
C4d-staining in peritubular capillaries and reappear-
ance of both remote DSA (A2 and B38) in high
quantities (Figure 2; picture 1A and 1B). The patient
received another course of IvIg, six steroid pulses and
four plasmapheresis treatments. Subsequently, serum
creatinine declined to 110 mmol/l.
Eight weeks post-transplant, increasing BK-virus
replication in the urine was noted along with the
appearance of numerous decoy cells, followed by
plasma BK-viral loads persisting above 10 000
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copies/ml. The diagnosis of ‘presumptive’ PVAN was
made [1] and immunosuppression reduced (tacrolimus
trough levels from 10–15 ng/ml to 6–8 ng/ml, MMF
dose from 2 to 1.5 g/day, further tapering of steroids).
Three weeks later, a second allograft biopsy was
performed. Dense focal lymphohistiocytic infiltrates
were seen, affecting 20% of the cortical and 35% of the
medullar area with mild tubulitis. There were numerous
SV40 antigen-positive tubular epithelial cells in the
medulla and in the cortex (Figure 2; picture 2A and 2B).
At this time-point, BK-viral loads were 3.9 1011
copies/ml in urine and 5.1 106 copies/ml in plasma,
respectively. The diagnosis of PVAN pattern B
was made and immunosuppression further reduced
(tacrolimus trough levels to 4–6 ng/ml, MMF dose to
0.5 g/day, steroids were tapered out over 8 weeks).
BK-viraemia remained constantly above 106 copies/
ml for 8 weeks, but then started to decline by two
log10 units to a plateau of around 4 104 copies/ml.
Within this time period, serum creatinine concentra-
tions slowly rose from 140 to 180 mmol/l. A third
allograft biopsy was performed, which showed massive
diffuse lymphohistiocytic infiltrates affecting 100% of
the cortical and medullar area with severe tubulitis.
There were only few SV40 antigen positive tubular
epithelial cells in the medulla and the cortex (Figure 2;
picture 3A and 3B). A presumed diagnosis of
BK-virus specific immune reconstitution was made.
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Fig. 1. Course of immunosuppressive therapy, allograft function, BK-virus activity and BK-virus serology within the first year after
transplantation. Stars with appended numbers in the serum creatinine graphic indicate allograft biopsies. The corresponding allograft
histologies are shown in Figure 2. PP, plasmapheresis; SM, solumedrol i.v.; IvIg, intravenous immunoglobulins; BK-virus-specific IgG and
IgM antibodies were measured in human sera using virus-like particles (VLP) as antigens coated to microtitre plates. BK-virus-like particles
were purified by density gradient centrifugation of lysates from Sf9 insect cells infected with recombinant BK-virus-VP1 Bac-to-Bac
expression vectors (Invitrogen). Antigen coating and serum dilutions provided optimal OD results at 50 ng and 1: 400, respectively
(S. Bodaghi and H.H. Hirsch, unpublished data).
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Immunosuppression consisting of tacrolimus with
trough levels of 4–6 ng/ml and MMF 0.5 g/day was
maintained and no additional therapy introduced.
Retrospective analysis of serum samples at this
time-point revealed newly produced BK-virus specific
IgM together with increasing IgG antibodies (Figure 1,
bottom panel) consistent with an emerging BK-virus
specific immune response.
Fig. 2. Allograft histology graded according to the Banff classification [16] and a recently proposed semi-quantitative assessment for PVAN
[1]. All allograft biopsies consisted of two cores obtained with a 16-gauge needle. First biopsy, 21 days post-transplant (cy0, i0t0, ci0ct0): the
tubulointerstitial compartment was completely normal, but there were fibrin thrombi in peripheral glomerular capillary loops (arrow)
consistent with thrombotic microangiopathy (1A). Peritubular capillaries (PTC) were diffuse positive for C4d by immunofluorescence (IF)
(1B). Staining for SV40 antigen by immunohistochemistry was negative. Second biopsy, 3 months post-transplant (cy3, i2t1, ci0ct0): dense
focal lymphohistiocytic infiltrates in the cortical and medullary interstitial space with mild tubulitis. Note enlarged nuclei (arrow) without
clear-cut inclusion bodies (2A). Glomeruli and arteries were completely normal. Staining for SV40 antigen revealed numerous infected tubular
epithelial cells in the cortex and medulla (2B). Staining for C4d in PTC and HLA-DR in tubular epithelial cells were negative. Third biopsy,
6 months post-transplant (cy1, i3t3, ci0ct1): massive diffuse lymphohistiocytic infiltrates affecting the whole cortical and medullary space with
severe tubulitis (3A). Immune phenotyping of the infiltrate revealed a very dominant fraction of T-cells (CD3þ) with equal amounts of CD4þ
and CD8þ cells, few macrophages (CD68) and few B-cells (CD20). Glomeruli and arteries were completely normal. Only few tubular
epithelial cells were positive for SV40 antigen (3B). Staining for C4d in PTC and HLA-DR in tubular epithelial cells were negative. Fourth
biopsy, 10 months post-transplant (cy0, i0t0, ci0ct0): both biopsy cores showed perfectly normal renal tissue (4A and 4B). No tubular
epithelial cells were positive for SV40 antigen. Staining for C4d in PTC and HLA-DR in tubular epithelial cells were negative.
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Ten weeks later, BK-viraemia became negative,
followed by clearance of the virus in the urine. Serum
creatinine declined and stabilized at 110–120mmol/l.
A follow-up biopsy showed normal allograft tissue
without any tubulointerstitial infiltrates, no tubular
atrophy and interstitial fibrosis and no SV40 antigen
positive tubular epithelial cells (Figure 2; picture 4A
and 4B). Testing for BK-virus-specific T-cells by
interferon-g ELISpot at this time-point revealed
a response against BK-virus large T and VP1 proteins.
Intracellular staining for interferon-g showed a promi-
nent large T- directed CD8þ T-cell response consistent
with an established cellular immune response
as reported previously (Figure 3) [9].
Discussion
The majority of patients with PVAN demonstrate
tubulointerstitial inflammation [6,10], which can
either indicate concurrent allograft rejection or an
inflammatory response to the BK-virus. The relative
contribution of these two entities is unknown and
specific single markers to separate them are currently
lacking. The clinico-pathological course of our patient
is intriguing and may serve as an index case of
BK-virus-specific immune reconstitution syndrome.
At the time of the third allograft biopsy showing
diffuse massive interstitial infiltrates and severe
tubulitis, circumstantial evidence suggested that acute
rejection was less likely as the cause. First, extensive
infiltrates were coincident with a significant decline of
BK-virus replication, indicated by a decreasing plasma
BK-viral load of >2 log10 units and a substantial
clearance from the allograft based on a significant
reduction of SV40 antigen-positive tubular epithelial
cells. Second, the increase of serum creatinine was only
moderate, despite severe tubulointerstital pathology.
Third, staining of tubular epithelial cells for HLA-DR
in frozen sections was available, which served as an
adjunctive tool to differentiate between tubulitis due
to rejection and PVAN. HLA-DR positivity is a typical
finding in Banff Ia/Ib rejection whereas it is mostly
negative in PVAN, as in this case and described
earlier [11]. However, the strongest argument against
an alloimmune-related inflammation was the clinico-
pathological course. Indeed, massive tubulointerstitial
infiltrates developed after immunosuppression was
significantly lowered, but they subsequently resolved
completely while maintaining the same low immuno-
suppression without having applied any rejection
treatment. A drug-induced interstitial nephritis is
also very unlikely, because no drugs were added or
discontinued within this time frame, with the exception
of tapering out prednisone and reducing tacrolimus
and MMF. Therefore, BK-virus-specific immune
reconstitution is the most probable explanation
for the observed clinico-pathological course, and to
the best of our knowledge there is no consistent
alternative diagnosis.
Support for this interpretation comes from retro-
spectively measured BK-virus-specific antibody titres
as a surrogate marker of the emerging immune
response to the BK-virus, as has been reported
previously [12]. A marked increase of BK-virus specific
IgM and IgG was noted following the decline of
plasma BK-virus load at the time of severe tubulo-
interstitial inflammation. Longitudinal analysis of
BK-virus specific cellular immune responses or char-
acterization of cellular infiltrates in the allograft would
have been of particular interest in this case [13],
but were not available. However, we analysed the
frequency of BK-virus specific interferon-g producing
0.45%
CD3+CD4+ CD3+CD8+
IFNg%IFNg%
B
K
 L
T 
pe
pt
id
es
CD
69
R
PM
I m
ed
iu
m
CD
69
B
0.92%
0.07%0.04%
 
  
   
    
     
      A 100,000
10,000
1,000
100
10
1
SEB BK LT BK VP1
SF
U 
pe
r m
ill
io
n 
PB
M
C
Fig. 3. BK-virus-specific interferon-g production in PBMC at
resolution of PVAN (i.e. at the time point of the fourth allograft
biopsy). The 15-mer peptide pools of 11 amino acid overlaps
spanning BK-virus large T-antigen (LT) and VP1 capsid protein
(VP1) were used for PBMC stimulation and interferon-g detection by
ELISpot assay (A) or by intracellular cytokine staining/flow
cytometry (B) as described previously [9]. Staphylococcus enterotoxin
B (SEB, SIGMA, Buchs, Switzerland, 1 mg/ml) and cell culture
medium served as positive and negative control, respectively.
The number of spot forming unit (SFU) per well was calculated
from triplicates after subtractions of negative control. By flow
cytometry, at least 30 000 CD3þ cells were acquired and analysed on
a FACS-Canto (Becton Dickinson). The frequency of BK-virus-
specific cellular immune responses was determined for each antigen
and expressed as percent of interferon-g positive cells among
CD3þCD4þCD69þ or CD3þCD8þCD69þ gated lymphocytes,
respectively.
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T-cells by ELISpot and flow cytometry after resolution
of PVAN, which were consistent with an established
cellular immune response against the BK-virus and in
line with our previous observation [9]. The reported
case suggests that integration of longitudinal dynamics
of BK-virus replication together with allograft func-
tion, histology and possibly markers of virus-specific
cellular and humoral immunity may currently be the
most valuable parameter for differentiation of tubu-
lointerstitial allograft rejection vs a BK-virus-specific
immune response.
An interesting finding in this case was the detection
of completely normal renal tissue in the last biopsy
despite severe tubulointerstitial inflammation and
many BK-virus infected tubular epithelial cells in
previous biopsies. This finding is surprising and may
indicate that the end-stage of PVAN characterized by
progressive tubular atrophy and interstitial fibrosis is
the result of ongoing tubular cell necrosis unbalanced
by regeneration [10]. Therefore, the good outcome in
the reported case could be related to an early and
efficient clearance of the BK-virus, or to a high
capacity of the allograft from a 7-year-old donor to
sustain injury and to regenerate. Although this single
case suggests that even severe inflammation due to
immune reconstitution may not be harmful, the value
of immunomodulatory drugs including steroids and
leflunomide as a treatment option to limit the extent of
inflammation is not clear yet. Notably, the immune
reconstitution syndrome is well-known in HIV/AIDS
patients and steroids are often considered when the
inflammation becomes damaging to an organ [14,15].
In conclusion, we report a case consistent with
BK-virus-specific immune reconstitution after reduc-
tion of immunosuppression for treating PVAN, lead-
ing to transient severe tubulointerstitial inflammation
and moderate allograft dysfunction. Clearly, no gen-
eral recommendations regarding diagnosis and treat-
ment of BK-virus specific immune reconstitution
syndrome can be made based on this single case.
Prospective studies with standardized management are
required to validate our findings and to further
elucidate aetiology and treatment of tubulointerstitial
infiltrates in patients with PVAN.
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